Back to top
more

Royalty Pharma (RPRX)

(Real Time Quote from BATS)

$26.82 USD

26.82
3,542,551

+0.38 (1.44%)

Updated Aug 13, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Financial - Miscellaneous Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Royalty Pharma (RPRX) Matches Q4 Earnings Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 0% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Royalty Pharma (RPRX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.82% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Royalty Pharma (RPRX)

by Zacks Equity Research

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Phillips Edison & Company, Inc. (PECO) Q3 FFO and Revenues Top Estimates

by Zacks Equity Research

Phillips Edison & Company, Inc. (PECO) delivered FFO and revenue surprises of 9.43% and 2.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Jackson Financial (JXN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Jackson Financial (JXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up

by Zacks Equity Research

Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

by Zacks Equity Research

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.28% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Regional Management (RM) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Regional Management (RM) delivered earnings and revenue surprises of 15.89% and 0.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Jackson Financial (JXN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Jackson Financial (JXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Primis Financial (FRST) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Primis Financial (FRST) delivered earnings and revenue surprises of 14.29% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests

by Zacks Equity Research

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.

Royalty Pharma (RPRX) Surges 5.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Royalty Pharma (RPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Royalty Pharma (RPRX) Lags Q1 Earnings Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of -15.28% and 3.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Synchrony (SYF) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Synchrony (SYF) delivered earnings and revenue surprises of 0.68% and 2.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Surges 5.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Royalty Pharma (RPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Royalty Pharma (RPRX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 5.80% and 3.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.